<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04947527</url>
  </required_header>
  <id_info>
    <org_study_id>2019-10-19</org_study_id>
    <nct_id>NCT04947527</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Evaluation of Anti-Caries Varnish</brief_title>
  <official_title>Phase 2 Efficacy &amp; Safety Evaluation of Advantage Anti-Caries Varnish for Primary Prevention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Advantage Silver Dental Arrest, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Advantage Silver Dental Arrest, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine the efficacy &amp; safety of Advantage Anti-Caries&#xD;
      Varnish for primary prevention. The objectives are:&#xD;
&#xD;
      1) To determine if Advantage Anti-Caries Varnish (test varnish) is superior to an active&#xD;
      control varnish (5% Sodium Fluoride, no Povidone-Iodine) in the prevention of caries lesions&#xD;
      in the primary dentition. Specifically, prevention of caries lesions in primary teeth that&#xD;
      either are sound, have only d1 (white spots) lesions or unerupted at baseline; and 2) To&#xD;
      document the safety of the test varnish.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single center randomized, double-blind, placebo-controlled, parallel-group trial.&#xD;
      The treatment group will be exposed at baseline and once every three to four months after&#xD;
      baseline for a maximum period of 24 months. The control group will be exposed to the control&#xD;
      varnish in the same manner. 254 subjects will be enrolled. Half will be randomized to each&#xD;
      arm. Subjects will be 10-20 mo of age and in good health. Children attending Maternal and&#xD;
      Child Health (MCH) Immunization and Well Child programs in Pohnpei State will be enrolled.&#xD;
      Primary Outcome Variables: 1) Surface-level dental caries lesions (d2-4mfs) at 24 months post&#xD;
      baseline; 2) Presence/Absence of dental caries lesions (d2-4mfs &gt;0) at 12 months post&#xD;
      baseline. Secondary Outcome Variable: Adverse Events&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is a single center randomized, double-blind, placebo-controlled, parallel-group trial.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>All study personnel except for designated personnel in the data center will be blinded to the participant treatment assignment. In order to maintain blinding and eliminate examiner bias, the staff member applying these varnishes will not perform the caries scoring exams.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Caries Increment</measure>
    <time_frame>24 months post baseline</time_frame>
    <description>Surface-level dental caries lesions (d2-4mfs) at 24 months post baseline&#xD;
Surface-level dental caries lesions (d2-4mfs) at 24 months post baseline&#xD;
Surface-level dental caries lesions (d2-4mfs) at 24 months post baseline&#xD;
Surface-level dental caries lesions (d2-4mfs) at 24 months post baseline Surface-level dental caries lesions (d2-4mfs)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Caries Incidence</measure>
    <time_frame>12 months post baseline</time_frame>
    <description>Presence/Absence of dental caries lesions (d2-4mfs &gt;0)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>24 months post baseline</time_frame>
    <description>Cumulative Adverse and Serious Adverse Events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">254</enrollment>
  <condition>Dental Caries in Children</condition>
  <arm_group>
    <arm_group_label>Test Varnish</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Anti-Caries Varnish. The active ingredients are 10% (w/v) Povidone-Iodine and 5% (w/v) Sodium Fluoride CAS.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Varnish</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Control Varnish. 5% (w/v) Sodium Fluoride .</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Test varnish</intervention_name>
    <description>A maximum of 0.2 mL will be applied to the teeth with a dental brush. Test or control varnish will be applied topically 4 times per year following enrollment and at each 3 to 4-month intervals.</description>
    <arm_group_label>Test Varnish</arm_group_label>
    <other_name>Advantage Anti-Caries Varnish</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>A maximum of 0.2 mL will be applied to the teeth with a dental brush. Test or control varnish will be applied topically 4 times per year following enrollment and at each 3 to 4-month intervals.</description>
    <arm_group_label>Control Varnish</arm_group_label>
    <other_name>Placebo Varnish</other_name>
    <other_name>Fluoride Varnish</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. The subject's parent or legal guardian must provide signed and dated informed consent&#xD;
             (parent permission form).&#xD;
&#xD;
          2. The subject's parent or legal guardian of the subject must be willing and able to&#xD;
             comply with study requirements.&#xD;
&#xD;
          3. The subject is a 10-20 months at the time of enrollment.&#xD;
&#xD;
          4. The subject must be in good general health as evidenced by parent report.&#xD;
&#xD;
          5. The subject will have at least 1 erupted tooth that is either sound or has only a d1&#xD;
             (white spots) lesion.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previous treatment with fluoride varnish&#xD;
&#xD;
          2. Known allergy to iodine&#xD;
&#xD;
          3. Diagnosis of thyroid disease&#xD;
&#xD;
          4. Chronic, prophylactic use of antibiotics&#xD;
&#xD;
          5. Treatment with another investigational drug or intervention within 30 days preceding&#xD;
             the Baseline Visit.&#xD;
&#xD;
          6. Visible cavities (d2-4)&#xD;
&#xD;
          7. Presence of intraoral pathology that would make assessment of post treatment soft&#xD;
             tissue ulcerations or inflammation impossible (child could be enrolled if problem is&#xD;
             treated and lesions cleared)&#xD;
&#xD;
          8. Parent anticipates the child will move from Pohnpei during the next 2 years.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Months</minimum_age>
    <maximum_age>20 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ohnmar K Tut, BDS Phil</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Peter M Milgrom, DDS</last_name>
    <phone>(206) 251-6831</phone>
    <email>drmilgrom@silverarrest.com</email>
  </overall_contact>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 24, 2021</study_first_submitted>
  <study_first_submitted_qc>June 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 1, 2021</study_first_posted>
  <last_update_submitted>June 24, 2021</last_update_submitted>
  <last_update_submitted_qc>June 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>sodium fluoride</keyword>
  <keyword>povidone iodine</keyword>
  <keyword>dental varnish</keyword>
  <keyword>primary dentition</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dental Caries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluorides</mesh_term>
    <mesh_term>Fluorides, Topical</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

